Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 29;12:6585–6595. doi: 10.2147/CMAR.S241383

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Shen et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

PI3K/AKT pathway mediates the sorafenib resistance of miR-98-5p on sorafenib-resistant cells in HCC. HCCLM3/Sor and Huh7/Sor cells were separately treated with DMSO, WM, anti-miR-98-5p + DMSO, or anti-miR-98-5p + WM. (A and B) The expression of p-PI3K, PI3K, p-AKT, and AKT were detected using Western blot. (C and D) The survival rates of resistant cells in combination with increasing concentrations of sorafenib and the IC₅₀ values to sorafenib were detected by CCK-8 assay. (E) Apoptotic resistant cells were counted using Flow cytometric analysis. (F and G) Western blot was applied to measure the expressions of Bcl-2 and Bax in resistant cells. (H and I) Transwell assay analysis for the migration and invasion abilities of resistant cells was carried out. *P<0.05.